Drs. Dabiri, Goreshi, Fischer, and Iwamoto are from the Department of Dermatology, Roger Williams Medical Center, Providence, Rhode Island. Dr. Tiger is the Department of Dermatology, Lahey Hospital & Medical Center, Burlington, Massachusetts.
The authors report no conflict of interest.
This case was part of a presentation at the 8th Cosmetic Surgery Forum under the direction of Joel Schlessinger, MD; November 30-December 3, 2006; Las Vegas, Nevada. Dr. Dabiri was a Top 10 Fellow and Resident Grant winner.
Correspondence: Ganary Dabiri, MD, PhD, 50 Maude St, 1st Floor, Department of Dermatology, Providence, RI 02908 (firstname.lastname@example.org).
Dermatologists create acute wounds in patients on a daily basis. Ensuring that patients achieve the most desirable cosmetic outcome is a primary goal for dermatologists and an important component of patient satisfaction. A number of studies have examined patient satisfaction following MMS.3,4 Patient satisfaction is an especially important outcome measure in dermatology, as dermatologic diseases affect cosmetic appearance and are related to quality of life.3,4
Timolol is a nonselective β-adrenergic receptor antagonist that is used in dermatology to treat IHs. In this preliminary study, the authors sought to determine if topical timolol applied to acute wounds following surgical removal of nonmelanoma skin cancers could improve the overall cosmetic outcome of acute surgical scars. The results showed that compared to control, topical timolol resulted in a more cosmetically favorable scar. The results are preliminary, and it would be of future interest to further study the effects of topical timolol on acute surgical wounds from a wound-healing standpoint as well as to further test its effects on the cosmesis of these wounds.